Dr. Ibrahim is a senior investigator at The Lundquist Institute at Harbor-University of California at Los Angeles (UCLA) Medical Center and a Professor at the David Geffen School of Medicine at UCLA. He is a Co-founder of NovaDigm Therapeutics which has developed the Candida albicans NDV-3A vaccine, which showed effiacy in protecting women from recurrent vulvovaginal candidiasis in a Phase 1b/2a clinical trial. Dr. Ibrahim is a world recognized leader in the pathogenesis of fungal infections, host-pathogen interactions and vaccine and antibody development. Dr. Ibrahim has participated in the design of several clinical studies, published >200 peer reviewed research articles, reviews and book chapters. Dr. Ibrahim's laboratory has been NIH funded continuously since 2003, is a consultant to several pharmaceutical companies, a regular reviewer of NIH study sections and scientific journals, and an elected fellow of the American Academy of Microbiology. Dr. Ibrahim has raised >$30 millions in funding from NIH, foundations and industry.
Terrence Cochrane has over 20 years of experience in business services, process development, quality control, manufacturing, quality assurance, validation, project management, scale-up, and the requirements to meet cGMP standards to enable clinical and commercial use by using contract external service providers.
Partner, Burger/Meyer, LLP
William Burger is an experienced and talented litigator who enjoys a broad litigation practice. Mr. Burger has >17 years of experience in corporate law development of startup companies. Mr. Burger received his Bachelor of Science from the University of California, San Diego in 2001, and his Juris Doctor from the University of California, Los Angeles in 2004. Prior to joining Burger | Meyer, LLP, Mr. Burger practiced at some of the largest law firms in the world, including Morrison & Foerster, and Troutman Sanders.